Pfizer Inc and Flatiron Health announced an expanded strategic collaboration to further integrate and increase the use of real-world data in Pfizer’s development of innovative targeted cancer medicines. Under the terms of the agreement, Pfizer will draw on de-identified, real-world datasets and analytical expertise from Flatiron Health to inform development strategies and activities for a number of clinical development projects across major tumor types, as well as jointly explore other innovative ways to drive clinical development innovation with real-world data.
The collaboration, which was first established in 2014, builds on recent pioneering work by Pfizer and Flatiron Health to incorporate real-world evidence as part of a regulatory submission to expand the area of use for one of Pfizer’s breast cancer medicines.
“Real-world data and evidence, and the technologies that capture and analyze them, are increasingly valuable ways for us to improve medicines development. They can augment the data we collect in traditional trials and enable greater efficiency and effectiveness in our clinical trial design and operations,” said Rod MacKenzie, Ph.D., Chief Development Officer and Executive Vice President, Pfizer. “We are pleased to expand our relationship with Flatiron Health as we continue to work with leading technology companies and transform clinical trials to better deliver breakthroughs to patients.”
The expanded collaboration will be governed by a Joint Steering Committee to set strategic objectives for the collaboration as well as oversee identification and execution of projects in support of these objectives. Collaborative projects will include datasets from tumor types such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Pfizer and Flatiron Health will explore appropriate venues to share learnings from these research projects, as well as broader implications for the application of real-world data, with the scientific and healthcare communities to further explore the role of real-world evidence in regulatory decision making.
“This collaboration is geared toward uncovering valuable insights to inform clinical development within Pfizer’s oncology portfolio, as well as identifying future areas of collaboration that will evolve the role of real-world evidence in bringing innovative cancer treatments to patients,” said Zach Weinberg, president and co-founder, Flatiron Health. “We believe that the use of real-world evidence holds the potential to significantly accelerate cancer research, and we are proud to expand our relationship with Pfizer Oncology, a leader in this space.”
About Pfizer Oncology
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma. Pfizer Oncology is striving to change the trajectory of cancer.
Pfizer Inc.: Breakthroughs that change patients’ lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com